Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hypertonic Saline in Moderate to Severe Asthmatics
NCT03556683Phase 1Completed
- Sponsor
- University of North Carolina at Chapel Hill
- Start
- Oct 2018
- Primary completion
- Jun 2024
- Modality
- Small Molecules, Device-based Delivery
- Countries
- 1
01
Overview
Phase 1, open-label trial of hypertonic saline in asthma (3 arms), sponsored by University of North Carolina at Chapel Hill. Primary endpoint: Change in Mucociliary Clearance From Baseline to 7% Post Hypertonic Saline Inhalation. Started Oct 2018; status: completed.
02
Drugs
hypertonic saline
03
Conditions
asthma
Beyond the preview
Go deeper on NCT03556683.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03556683.